Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
Analyzing the Build It in America Act: Proposals for Business Tax Reform
Last week, the House Committee on Ways and Means released three tax bills, and this week the Committee will meet to consider these measures.
MGA’s Latest: A Look at Community Health Centers
MGA’s state-by-state analysis of Community Health Centers’ economic impact.
Flawed Approach: The Working Families Tax Cut Act as a Response to Inflation
Earlier this week, Congresswomen Nicole Malliotakis (R-NY) and Michelle Steel (R-CA), who are both members of the House Committee on Ways and Means, introduced the Working Families Tax Cut Act.
- Alex Brill Featured in Axios
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
